Aktis Oncology AKTS
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$1.64M (5 inflow days, 15 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 46.7% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 6.20% to 7.96% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +566,470 | 1.9% |
| BlackRock | Mutual Fund | 2026/Q3 | +502,387 | 5.0% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +363,850 | 2.1% |
| Geode Capital Management, LLC | Mutual Fund | 2026/Q3 | +169,690 | 1.2% |
| TD Asset Management | Mutual Fund | 2026/Q3 | +97,592 | 0.4% |
| Mirador Capital Partners, LP | Mutual Fund | 2026/Q3 | +93,434 | 0.2% |
| BNP Paribas Financial Markets SNC | Private Company | 2026/Q3 | +67,536 | 0.1% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +53,166 | 0.4% |
| Morgan Stanley Investment Management Inc. | Mutual Fund | 2026/Q3 | +28,933 | 0.2% |
| Curran Financial Partners, LLC | Mutual Fund | 2026/Q3 | +52,588 | 0.1% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +41,719 | 0.1% |
| TCG Crossover Management, LLC | VC/PE Fund | 2026/Q3 | +696,560 | 1.3% |
| BlackRock | Mutual Fund | 2026/Q3 | +166,231 | 4.1% |
| Barclays PLC | Public Company | 2026/Q3 | +146,282 | 0.3% |
| Renaissance Technologies Corp. | Hedge Fund | 2026/Q3 | +95,400 | 0.2% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 22 Sep 2026 | Akos Czibere | Chief Medical Officer | Derivative Exercise and Sale | -12,500 | $21.03 | – |
| 19 Jul 2026 | Ken Herrmann | Chair of Scientific Advisory Board & Independent Director | Derivative Exercise and Sale | -4,856 | $24.56 | – |
| 16 Jul 2026 | Ken Herrmann | Chair of Scientific Advisory Board & Independent Director | Derivative Exercise and Sale | -3,065 | $25.21 | – |
| 7 Jul 2026 | Shulamit Ron-Bigger | Chief Operating Officer | Derivative Exercise and Sale | -50,000 | $28.75 | – |
| 7 Jul 2026 | Akos Czibere | Chief Medical Officer | Derivative Exercise and Sale | -50,000 | $28.71 | – |
| 11 Jan 2026 | MPM BioImpact LLC | Private Acquisition | +1,112,777 | $18.00 | 10,260,064 | |
| 11 Jan 2026 | MPM BioImpact LLC | Derivative Exercise and Retained | +8,208,187 | – | 10,260,064 | |
| 11 Jan 2026 | Eli Lilly and Company | Initial Statement of Beneficial | +0 | – | 6,344,114 | |
| 11 Jan 2026 | Lloyd Segal | Independent Director | Derivative Exercise and Retained | +19,631 | – | 19,631 |
| 11 Jan 2026 | EcoR1 Capital, LLC | Private Acquisition | +2,222,222 | $18.00 | 4,824,469 | |
| 11 Jan 2026 | EcoR1 Capital, LLC | Derivative Exercise and Retained | +2,602,247 | – | 4,824,469 | |
| 11 Jan 2026 | Vida Ventures Advisors, LLC | Private Acquisition | +835,000 | $18.00 | 5,829,212 | |
| 11 Jan 2026 | Vida Ventures Advisors, LLC | Derivative Exercise and Retained | +4,994,212 | – | 5,829,212 | |
| 7 Jan 2026 | MPM BioImpact LLC | Initial Statement of Beneficial | +0 | – | 597,393 | |
| 7 Jan 2026 | Todd Foley | Chairperson | Initial Statement of Beneficial | +0 | – | 37,866 |
| 7 Jan 2026 | Helen Kim | Former Independent Director | Initial Statement of Beneficial | +0 | – | 37,866 |
| 7 Jan 2026 | Michael Sherman | Independent Director | Initial Statement of Beneficial | +0 | – | 93,846 |
| 7 Jan 2026 | Lloyd Segal | Independent Director | Initial Statement of Beneficial | +0 | – | 6,489 |
| 7 Jan 2026 | Mary Thistle | Independent Director | Initial Statement of Beneficial | +0 | – | 93,846 |
| 7 Jan 2026 | Matthew Roden | Chief Executive Officer | Initial Statement of Beneficial | +0 | – | 2,149,409 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 4,425,903 | 8.0% | 16.0 |
| 15 Oct 2026 | 4,313,744 | 7.8% | 11.3 |
| 30 Sep 2026 | 4,715,294 | 8.5% | 7.3 |
| 15 Sep 2026 | 3,252,475 | 5.8% | 11.5 |
| 31 Aug 2026 | 3,175,040 | 5.7% | 10.4 |
| 14 Aug 2026 | 3,447,126 | 6.2% | 15.0 |
No comments yet — be the first to weigh in on AKTS.
Sign in to join the discussion.